TickerTalks
Browse all tickers →
TickerTalks›$AZTA
AZAZTA

Azenta, Inc.

$AZTA·$1.5B·Medical - Instruments & Supplies·Healthcare
$32.81-0.4%YTD-9.9%1Y+10.1%
Mentions · last 7 days
2026-08-21: 0 posts2026-08-22: 0 posts2026-08-23: 0 posts2026-08-24: 13 posts180%
Price updated 5m ago·X counts updated 7d ago
AZAZTA
$AZTAAzenta, Inc.
$32.81-0.42%18 posts0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $AZTA, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Comeback attemptAcceleratingAI verdict · as of 2026-08-21

The move is getting stronger, with heavier trading behind it.

Sample-management supplier printing a 40% beat with a fresh acquisition and an insider buy — the turnaround is landing.

Azenta provides sample-management technology to life-sciences labs — automated cold storage, sample tracking, genomics services — and completed the B Medical Systems acquisition on Jul 1 to add medical cold-chain equipment for vaccine distribution. The equity is a bet on lab-services demand recovery plus successful M&A integration.

  • Q4 fiscal EPS came in at $0.16 vs $0.114 consensus — a 41% beat and the fourth beat in five quarters, with revenue growing modestly at $161M; the operating leverage on the recovery is what's driving the EPS surprise rather than a top-line explosion.
  • On Jul 31 director Ephraim Starr filed a P-Purchase of $8K at $24.17 — small dollar-value, but a director buying with cash into a name that had just started to work is a real signal on management conviction.
  • Trades below any coherent TTM P/E on GAAP because the LTM includes losses, but forward 2026 fiscal consensus EPS of $0.39 works out to ~94x; that number matters less than the trajectory (2028 estimate is $0.85, so the multiple compresses fast if the beat cadence continues).
  • Sits at the 80th percentile of its 52-week range and is 33% above the 50-day trend — the tape is genuinely running, driven by the beat and the B Medical acquisition close.

What sustains the acceleration is Nov 17 fiscal Q1 confirming B Medical integration coming through at accretive margins alongside continued lab-services recovery — both together back the 2026-2028 EPS ramp. What invalidates it is a soft B Medical revenue print (integrations often stumble on the first full-quarter comparison), or a life-sciences funding-environment wobble that hits Azenta's lab-tools customer base.

Agrees with X sentimentThe X read is heavily options-driven around the double-beat gap-fill setup, which is a legitimate short-term signal but not a fundamental case. The underlying story (B Medical acquisition, beat cadence, insider buy) does justify the direction; the crowd's evidence is thinner than the actual case.

What to watch: Nov 17 fiscal Q1 earnings — first full-quarter B Medical revenue and margin contribution. Life-sciences customer commentary on funding environment would be the read on the underlying market.

On the calendar: 2026-11-17 — Fiscal Q1 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-08-12

Azenta traders are booking 16-33% returns on the August $35 calls at $0.60-$0.80 following a double beat, price-target upgrades and a gap-fill play setup. Options momentum is uniformly constructive and there are no bearish voices in the sample.

Read the AI verdict + X sentiment for $AZTA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Provides biological sample storage, genomics sequencing services, and automated lab equipment to pharma and biotech researchers.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Instruments & Supplies sits in its cycle right now — and what that implies for $AZTA.

Medical - Instruments & Supplies · Healthcare

Life science tools demand is tied to pharma/biotech R&D budgets; GLP-1 clinical development is a current bright spot driving CRO and instrument demand. Academic and government research funding is the more volatile demand component.

What this means for $AZTA

Partial — branded pharmaceutical revenue is exposed to patent cliff dynamics and GLP-1 category cannibalization; Azenta, Inc.

Industry benchmark

10-name peer basket
+22.1%YTD
+25.1%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-5.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-0.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-2.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
2.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-10.7%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
44.6%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$0.16$0.11+40.6%
Q1 2026May 6, 2026$-0.04$0.10-140.0%
Q4 2025Feb 4, 2026$0.09$0.11-18.2%
Q3 2025Nov 21, 2025$0.21$0.19+10.8%
Next earningsFri, Nov 20·consensus EPS $0.16

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$144.8M+1.0%42.8%-10.6%$-3.49$4.8M
Q1 FY26$148.6M+0.8%42.9%-3.3%$-0.34$14.7M
Q4 FY25$159.2M+5.7%45.4%1.8%$1.03$-5.7M
Q3 FY25$143.9M-0.2%47.1%1.1%$-1.15$15.0M

Forward consensus

5-year forecast · up to 4 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$600.5M$590.4M – $603.7M$0.39$0.38 – $0.394
FY27$630.1M$619.6M – $633.5M$0.61$0.60 – $0.624
FY28$675.0M$663.7M – $678.7M$0.85$0.80 – $0.894
FY29$683.5M$672.0M – $687.2M$1.30$1.27 – $1.312
FY30$742.8M$730.3M – $746.8M$1.76$1.72 – $1.772

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.66%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+14.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+16.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 40.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.385-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyJul 31Ephraim StarrSVP, Gen Counsel & Secretary335 sh$8KBuyMay 18William L CornogDirector10.0K sh$164K
+ 3 other (2 inkinds · 1 award) in window

See when $AZTA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeAug 248-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

Azenta, Inc. (AZTA) disclosed a CEO transition effective August 22, 2026. John P. Marotta resigned as President, CEO, and board member with no disagreement cited; the board was simultaneously reduced from nine to eight members. Dr. Martin D. Madaus, previously Chair of the Nominating and Governance Committee, was appointed Interim President and CEO and will step down from his governance committee roles during his interim tenure. Compensation terms for the interim role were not disclosed in the excerpt. An unplanned CEO departure and an interim appointment signal strategic transition risk while a permanent search is underway.

8-KOfficer or director changeAug 118-K — Item 5.02: Officer or director change
AI summary

Azenta (AZTA) appointed Erik J. Bello, age 51, as Vice President and Chief Accounting Officer, effective August 31, 2026, serving as principal accounting officer. Lawrence Lin continues as EVP and CFO. This is a routine accounting officer appointment.

8-KMaterial agreementJul 88-K — Item 1.01: Material agreement · Item 2.01: Acquisition completed · Item 7.01: Press release / Reg FD
AI summary

Azenta, Inc. (AZTA) completed the acquisition of B Medical Systems S.à r.l. from Thelema S.à r.l. on July 1, 2026. To facilitate closing, Azenta Germany GmbH provided Thelema a $35 million vendor loan at 6.0% per annum, secured by a pledge over 100% of B Medical Systems' equity, maturing 3 months after funding — a related-party transaction approved by the Audit Committee (Thelema is majority owned by VP/B Medical Systems CEO Luc Provost). The acquisition is complete with B Medical Systems now a wholly-owned subsidiary; the $35M vendor loan is a short-term bridge expected to be refinanced.

3New insider — initial holdingsApr 163
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3 (initial ownership statement) for AZTA on 2026-04-16, initiating required Section 16 reporting. Role: of Reporting Person. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

8-KOfficer or director changeApr 78-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

AZTA disclosed a personnel change (8-K Item 5.02, dated 2026-04-07). An executive departure and a new appointment are both reported. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

8-KMaterial agreementMar 48-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
+ 9 other (2 10-Qs · 2 earnings 8-Ks · 2 13Gs · 1 SD) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

7,529,450 Shares in Azenta, Inc. $AZTA Acquired by BlackRock Inc.defenseworld.net·4d agoINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTAprnewswire.com·4d agoAmerican Capital Management Inc. Buys Shares of 1,061,490 Azenta, Inc. $AZTAdefenseworld.net·5d agoINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTAglobenewswire.com·6d agoAZENTA ANNOUNCES LEADERSHIP TRANSITIONprnewswire.com·7d ago

In themes

Explore the broader themes this ticker is being talked about under.

Robotics & HumanoidsAI Precision Medicine

More in Medical - Instruments & Supplies

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$BDX$ISRG$MDLN$AVTR$QDEL$RGEN$WST$PLSE
Voices on X · last 7 days

No standout posts about $AZTA on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport